Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
INTREPId trial: what clinicians have said so far
INTREPId (INTermediate Risk Erection PreservatIon Trial)
- NCT04025372 ↗
- Active, not recruiting
- Brigham and Women's Hospital
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on INTREPId yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on INTREPId so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- INTREPId (INTermediate Risk Erection PreservatIon Trial): A Randomized Trial of Radiation Therapy and Darolutamide for Prostate Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Prostate Cancer
- Interventions
- Bicalutamide; GnRH Agonist; Radiation Therapy; Darolutamide
- Arms
- Bicalutamide+GnRH Agonist+Radiation Therapy · Experimental
- Darolutamide+Radiation Therapy · Experimental
- Enrollment
- 234
- Primary outcomes
- The percentage of patients with a PSA nadir <= 0.5
- Sponsor
- Brigham and Women's Hospital with Bayer, Decipher Biosciences
- Start
- Jun 1, 2020
- Primary completion
- Oct 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04025372 · updated Dec 15, 2025
Publications
linked from the registry- Roy A, Green O, Brenneman R, Bosch W, Gay HA, Michalski JM, Baumann BC. Assessing Inter-Fraction Changes in The Size and Position of The Penile Bulb During Daily MR-Guided Radiation Therapy to The Prostate Bed: Do We Need to Adjust How We Plan Radiation in The Post-Radical Prostatectomy Setting to Reduce Risk of Erectile Dysfunction? Clin Genitourin Cancer. 2022 Jun;20(3):e227-e232. doi: 10.1016/j.clgc.2022.01.006. Epub 2022 Jan 11. PubMed 35153154